PHI LIFE SCIENCES, LLC
CHARLESTON, SC

Phi Life Sciences, LLC is a Molecular Diagnostic and Laboratory Service company founded on April 29, 2016. The company is headquartered at the SCRA MUSC Innovation Center, located at 645 Meeting Street, Suite 3, Charleston, SC 29403. With its focus on reducing disease mortality and adverse drug reactions, Phi Life Sciences offers affordable, state-of-the-art screening and diagnostic technologies. It serves as a crucial bridge between innovative scientific technology developers and the patients and doctors who can benefit from these advancements. Phi Life Sciences is dedicated to improving healthcare standards by facilitating early disease detection and precision medicine management. The company promotes a 'bench to bedside' approach by providing cutting-edge diagnostic tools that enable effective treatment strategies at early disease stages, enhancing patient health outcomes. The innovative team behind Phi Life Sciences brings over 40 years of experience in the molecular diagnostics field, with a proven track record in clinical research programs under CMS and FDA regulations. They have also been involved in developing proprietary and licensed technologies as well as educational outreach related to molecular diagnostic media. Their clinical support team assists healthcare professionals in interpreting results and optimizing patient care. Operating from South Carolina, Phi Life Sciences is incorporated as a Florida entity with the company type FORL, incorporating on January 11, 2017. The company maintains its corporate registration under the filed number M17000000317 and is listed in Duval County, SC, although it was originally registered in Jacksonville, FL (FEI Number: 81-2542375). Phi Life Sciences utilizes advanced diagnostic technologies such as Genotyping, Gene Expression, Next Generation Sequencing, and provides study design support alongside a range of services compliant with CLIA, CAP, GLP, and ICH E15 standards. Phone contact is available at (888) 576-5445 for further inquiries. The organization's last significant event was its reinstatement on November 1, 2019, and it plans to submit an annual report for the year 2024 on April 22, 2024. Key officers managing Phi Life Sciences include Sawan Hurst, Robert Barfield, and Dorothy Fitzsimmons.